Also trades as GMAB.

GMAB.CO

Premium GrowerAI neutral

Genmab A/S · Healthcare · Denmark · $24.4B cap · $109.6M/day traded

DKK 3,581.00 -2.2% · close 10 Nov · scored 11 Nov

Premium Grower: Strong business with the market behind it, priced at a premium.

69
Score
Get score and insider alerts

Around its 5 Nov results, analysts cut next year's EPS estimate 4.4%.

Quality
60
Value
26
Momentum
79

As of 11 Nov 2026, the MoatMap Score for Genmab A/S (GMAB.CO) is 69/100, ranked against 25,000+ stocks in 38 markets (Quality 60, Value 26, Momentum 79, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
46.9x
peers 14.3x
ROE
12.1%
peers 15.9%
D/E
0.8x
peers 0.2x
Dividend %
—
trailing yield
AI REVIEW

Genmab is a Danish antibody biotech with high-margin royalties, mainly from J&J's Darzalex, and a growing own-product portfolio. It has a strong net cash balance sheet and credible science. However, royalty concentration on Darzalex creates a patent cliff later in the decade, and the value case depends on pipeline and acquisition execution. The available news gives no fresh catalyst.

ABOUT GENMAB A/S

Read

Genmab A/S is an international biotechnology company focused on the creation and development of differentiated antibody therapeutics for cancer and other serious diseases. Its competitive moat lies in its proprietary antibody technology platforms, such as DuoBody and HexaBody, which enable the development of novel and highly effective drug candidates. Genmab is a specialized and innovative biotech firm with a strong pipeline and a proven track record of bringing successful cancer treatments to market through strategic partnerships.

FINANCIAL SUMMARY (DKK)

Reported in USD

Year20212022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue—14.7B16.5B21.5B24.6B18.6%28.6B31.5B38.2B24.2%
EPS (DKK)7.0085.8266.61117.50102.3695.5%74.7174.38106.651.6%
Shares—65.4M65.3M63.5M61.6M-5.8%61.5M———
Debt—599.3M767.7M1.0B34.5B286.1%34.6B———
Equity—27.4B31.6B36.8B37.2B10.7%————
Op CF—4.0B7.4B7.8B7.8B25.4%5.8B———
Inv CF—-2.8B-1.3B-10.0B-37.3B—————
Fin CF—-801.8M-613.0M-3.9B31.6B—————
PRICE (1Y) · DKK+52.8%
2,2572,6713,0853,4983,91230 Sep21 Oct10 Nov
SMA 50SMA 200

Price checkIn an uptrendExperimental

Above its 200-day average and 9% below its 52-week high.

SwingsBumpy

Swung more than 58% of stocks we rank over the past year (volatility 47% a year).

How this is worked out

The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
DKK 3,581.00
RSI (14)
71.6
52-Week Range-9.3% from high
Low DKK 1,512.00High DKK 3,947.00

SCORE BREAKDOWN

Quality
60
ROIC
10.1%69.6
ROE
12.1%74.8
GP/Assets
30.9%66.2
Op. Margin
37.2%95.4
FCF/Assets
6.5%75.1
Piotroski
431.1
Int. Cover
3.1x45.8
D/E Ratio
0.82x17.0
Current Ratio
2.45x48.2
Value
26
P/E (TTM)
46.9x21.6
EV/EBITDA
24.9x24.4
P/FCF
28.9x32.9
P/B
5.5x21.1
P/S
7.5x28.7
Div Yield
—N/A
Momentum
79
52W High %
91%84.2
RS 6M
95%97.1
SMA 50/200
1.30x94.7
EPS Rev 4W
+4.8%92.0
EPS Rev 12W
+10.1%85.6
EPS Improve
+54%57.5
Q Growth
-15%28.1

FUNDAMENTALS

Market Cap
$24.4B
P/E (Forward)
30.5x
Gross Margin
92.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GMAB.CO are excluded.

TickerCompanyMkt CapScore
GMAB.COGenmab A/S(you)$24.4B69
ALK-B.COALK-Abelló A/S$8.1B75
ASNDAscendis Pharma A/S$16.0B47
ZEAL.COZealand Pharma A/S$2.2B70
BAVA.COBavarian Nordic A/S$2.8B98
GUBRA.COGubra A/S$711M32
SANION.STSaniona AB (publ)$153M79
COLO-B.COColoplast A/S$16.4B86
DEMANT.CODemant A/S$11.3B80
GN.COGN Store Nord A/S$2.4B66

Peer medians: ROE 15.9% · P/E 14.3x · Gross margin 82.1%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Genmab A/S (GMAB.CO): Stock Score Summary

Genmab A/S (GMAB.CO) has a MoatMap Score of 69/100 based on Quality (60/100), Value (26/100), and Momentum (79/100) factor scores. Genmab is a Danish antibody biotech with high-margin royalties, mainly from J&J's Darzalex, and a growing own-product portfolio. It has a strong net cash balance sheet and credible science. However, royalty concentration on Darzalex creates a patent cliff later in the decade, and the value case depends on pipeline and acquisition execution. The available news gives no fresh catalyst.

Genmab A/S is an international biotechnology company focused on the creation and development of differentiated antibody therapeutics for cancer and other serious diseases. Its competitive moat lies in its proprietary antibody technology platforms, such as DuoBody and HexaBody, which enable the development of novel and highly effective drug candidates. Genmab is a specialized and innovative biotech firm with a strong pipeline and a proven track record of bringing successful cancer treatments to market through strategic partnerships.

Director dealings

From 11 Nov 2025 to 11 Nov 2026, MoatMap's records hold 2 sales and 2 purchases of Genmab A/S (GMAB.CO) shares by its directors. The largest: Jan van de Winkel bought 8,525 shares at DKK 1,758.50 on 1 Apr 2026 (about DKK 15.0M).

  • 29 May 2026: Michael Kavanagh sold 221 shares at DKK 1,734.75 (about DKK 383K)
  • 1 Apr 2026: Jan van de Winkel bought 8,525 shares at DKK 1,758.50 (about DKK 15.0M)
  • 2 Mar 2026: Jan van de Winkel bought 567 shares at DKK 1,867.50 (about DKK 1.1M)
  • 19 Feb 2026: Anthony Pagano sold 899 shares at DKK 1,810.00 (about DKK 1.6M)
GMAB.CO insider filings, last 180 days

Key Financial Metrics

PriceDKK 3,581.00
Market Cap$24.4B
P/E (TTM)46.87
P/E (Forward)30.50
Price/Book5.53
Return on Equity12.1%
Return on Invested Capital10.1%
Debt/Equity0.82x
Gross Margin92.7%
Operating Margin37.2%
Revenue Growth16.1%
Free Cash Flow$843M

Genmab A/S operates in the Biotechnology industry, part of the Healthcare sector (Denmark).

Frequently Asked Questions

What is Genmab A/S’s (GMAB.CO) MoatMap Score?
The MoatMap Score for Genmab A/S (GMAB.CO) is 69/100. It is a composite of Quality (60), Value (26), and Momentum (79), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Genmab A/S have an economic moat?
Genmab A/S (GMAB.CO) has a Quality factor score of 60/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Genmab A/S in?
Genmab A/S (GMAB.CO) operates in the Healthcare sector, specifically the Biotechnology industry (Denmark).